tradingkey.logo

Lexeo rises as it announces leadership changes

ReutersJan 27, 2026 1:31 PM

Shares of drug developer Lexeo Therapeutics LXEO.O rise 2% to $7.63 premarket

Co says it named cardiologist Dr. Narinder Bhalla as chief medical officer

Co says its research head Dr. Eric Adler will become CEO of Myoventive, which focuses on RNA-based treatments for inherited heart conditions

CTO José Manuel Otero moves to the chief operating officer's role; co also hires two VPs to lead early- and late-stage cardiology programs - LXEO

Shares up ~51% in 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI